scholarly journals High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors

Cancer ◽  
2008 ◽  
Vol 112 (6) ◽  
pp. 1345-1353 ◽  
Author(s):  
Chie-Schin Shih ◽  
Gregory A. Hale ◽  
Lindsey Gronewold ◽  
Xin Tong ◽  
Fred H. Laningham ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Malignant Brain Tumors ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

High-dose Chemotherapy With Autologous Stem Cell Rescue in Saudi Children Less Than 3 Years of Age With Embryonal Brain Tumors

2015 ◽  
Vol 37 (3) ◽  
pp. 204-208 ◽  
Author(s):  
Abdulrahman Alsultan ◽  
Musa Alharbi ◽  
Sadeq Al-Dandan ◽  
Yasser Bayoumi ◽  
Talal Alharbi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Embryonal Brain ◽  
Autologous Stem Cell Rescue

scholarly journals High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single Institution Experience from UCLA

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Eduard H. Panosyan ◽  
Alan K. Ikeda ◽  
Vivian Y. Chang ◽  
Dan R. Laks ◽  
Charles L. Reeb ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
Hematopoietic Stem Cell ◽  
Germ Cell Tumors ◽  
Pediatric Brain Tumors ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Pediatric Brain

Background. Dose-dependent response makes certain pediatric brain tumors appropriate targets for high-dose chemotherapy with autologous hematopoietic stem-cell rescue (HDCT-AHSCR).Methods. The clinical outcomes and toxicities were analyzed retrospectively for 18 consecutive patients ≤19 y/o treated with HDCT-AHSCR at UCLA (1999–2009).Results. Patients' median age was 2.3 years. Fourteen had primary and 4 recurrent tumors: 12 neural/embryonal (7 medulloblastomas, 4 primitive neuroectodermal tumors, and a pineoblastoma), 3 glial/mixed, and 3 germ cell tumors. Eight patients had initial gross-total and seven subtotal resections. HDCT mostly consisted of carboplatin and/or thiotepa ± etoposide (n=16). Nine patients underwent a single AHSCR and nine ≥3 tandems. Three-year progression-free and overall survival probabilities were 60.5% ± 16 and 69.3% ± 11.5. Ten patients with pre-AHSCR complete remissions were alive/disease-free, whereas 5 of 8 with measurable disease were deceased (median followup: 2.3 yrs). Nine of 13 survivors avoided radiation. Single AHSCR regimens had greater toxicity than ≥3 AHSCR (P<.01).Conclusion. HDCT-AHSCR has a definitive, though limited role for selected pediatric brain tumors with poor prognosis and pretransplant complete/partial remissions.

Sign in / Sign up

Export Citation Format

Share Document